Total trials
200
Active
28
Phase 3
24
Total enrollment
232,840
Pipeline matrix
Showing 14 of 14 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dapagliflozin 10 mg | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 2 | |
| Rituximab | — | — | — | — | 4 | ||
| Lenalidomide | — | — | — | — | 2 | ||
| Daratumumab | — | — | — | — | — | 1 | |
| Pembrolizumab plus Chemotherapy | — | — | — | — | — | 1 | |
| Tafasitamab | — | — | — | — | — | 1 | |
| Methotrexate | — | — | — | — | — | 1 | |
| BrECADD | — | — | — | — | — | 1 | |
| Tislelizumab | — | — | — | — | — | 1 | |
| Tarlatamab, Carboplatin, Etoposid | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 | |
| Olaparib | — | — | — | — | — | 1 | |
| Cablivi® | — | — | — | — | — | 1 |
Next readouts
- 2025-03-15
- 2026-05
- 2026-05
- 2026-06
- 2026-09
- 2027-01
- 2027-02
- 2028-01
- 2030-05-15
- 2031-06-30
Top conditions
- Hodgkin Lymphoma9
- Classical Hodgkin Lymphoma7
- Schizophrenia6
- Hyponatremia5
- Hodgkin´s Lymphoma4
- Multiple Myeloma3
- Tic-Disorder3
- SARS-CoV-2 Infection3
Frequently asked questions about University of Cologne
- How many clinical trials does University of Cologne have on ClinicalTrials.gov?
- University of Cologne is listed as the lead sponsor on 200 clinical trials in ClinicalTrials.gov, 28 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Cologne's trials are in Phase 3?
- 24 of University of Cologne's trials are in Phase 3, spread across 14 active drug programs.
- What therapeutic areas does University of Cologne focus on?
- University of Cologne's most-studied conditions on ClinicalTrials.gov are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Schizophrenia, Hyponatremia, Hodgkin´s Lymphoma.
- When are University of Cologne's next clinical trial readouts?
- University of Cologne has 10 upcoming primary-completion readouts tracked here; the soonest is “Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse”, expected around 2025-03-15.